New cell therapy targets hard-to-treat cancers with KRAS mutation
NCT ID NCT07014878
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new treatment called DCTY1102 for people with advanced cancers (like pancreatic, colorectal, or lung cancer) that have a specific genetic change (KRAS/NRAS G12D mutation) and a certain immune type (HLA-A*11:01). The treatment uses the patient's own immune cells, modified in a lab to better attack the cancer. The main goals are to check safety, find the best dose, and see if it shrinks tumors. Only 18 participants will be enrolled initially.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, 200032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Jiangsu Province Hospital
Shanghai, Shanghai Municipality, 210029, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can we predict who will survive a bowel surgery leak?
- Can High-Dose vitamin c boost Chemo's punch against pancreatic cancer?
- Can a Two-Drug attack shrink Hard-to-Treat colorectal tumors?
- Breathing tube-free lung surgery tested for patients with fragile lungs
- Can standard cancer treatment wake up the immune system? a study investigates.
- Can a cancer pill keep working outside the lab? a Real-World test begins